Johnson & Johnson reported better-than-expected Q2 2026 results with adjusted EPS of $2.90, surpassing estimates, and revenue of $25.31 billion, driven by strong pharmaceutical sales. Key growth came from the Innovative Medicine segment, with notable sales from Tremfya and Darzalex offsetting patent losses on older drugs. The company raised its full-year 2026 guidance to $100.8-$101.4 billion in sales and adjusted EPS of $11.60-$11.75. CEO Joaquin Duato highlighted recent product approvals and a strong innovation pipeline, signaling confidence in reaching over $100 billion in annual revenue for the first time in its history.
Johnson & Johnson reported strong Q2 sales of $584 million for Spravato, a nasal spray for treatment-resistant depression, signaling robust market potential for psychedelic drugs. Jefferies highlights this growth supports the commercial viability of ...
Johnson & Johnson reported solid Q2 2026 results, achieving 6.6% annual revenue growth driven by strong Pharma and MedTech divisions. The company maintains a portfolio of over 15 blockbuster drugs and a promising pipeline, supporting its status as a ...
The FTSE 100 dropped 23 points to 10,506, pressured by mining stocks reacting to China's slower-than-expected 4.3% GDP growth in Q2, its weakest in three years. European markets also declined, while US futures rose, led by tech. PayPal shares surged ...
US stock futures rose after a softer-than-expected Consumer Price Index (CPI) report reduced the chances of a Federal Reserve rate hike in July. The market now awaits today's Producer Price Index (PPI) data, which could either confirm easing inflatio...
Genmab announced that DARZALEX (daratumumab) achieved net trade sales of $4.207 billion globally in Q2 2026, with $2.435 billion from the U.S. and $1.772 billion from other regions. Genmab earns royalties on these worldwide sales through its licensin...
